Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Lexaria Bioscience Corp. (NASDAQ: LEXX) Optimistic About its Expanded DehydraTECH Investigations; Plans for More Studies in 2022 By: Investor Brand Network February 23, 2022 at 10:20 AM EST Lexaria just announced ground-breaking findings from its recently-concluded Sildenafil animal studyThe success of this study sets the stage for various other studies on the use of the company’s patented DehydraTECH technologyThe company is set to commence dosing its most extensive hypertension study in April 2022, with results expected in Q3 2022Its successful completion could greatly enhance Lexaria’s leadership position in the global drug delivery market Lexaria Bioscience (NASDAQ: LEXX) kicked off the 2022 calendar year by receiving independent review board approval for its upcoming DehydraTECH(TM)-CBD human hypertension study, HYPER-H21-4. Additionally, in what marks another critical milestone, the company also reported ground-breaking findings from its sildenafil animal study. Chris Bunka, the Lexaria’s Chief Executive Officer (“CEO”), at the beginning of the year, noted the company’s commitment to achieving even more milestones with its patented DehydraTECH technology for… Read More>> NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX About CBDWire CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge. Receive Text Alerts from CBDWire: Text “Cannabis” to 21000 For more information please visit https://www.cbdwire.com and or https://CBDWire.News Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer CBDWire (CBDW)Denver, Coloradocbdwire.com303.498.7722 OfficeEditor@CBDWire.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Lexaria Bioscience Corp. (NASDAQ: LEXX) Optimistic About its Expanded DehydraTECH Investigations; Plans for More Studies in 2022 By: Investor Brand Network February 23, 2022 at 10:20 AM EST Lexaria just announced ground-breaking findings from its recently-concluded Sildenafil animal studyThe success of this study sets the stage for various other studies on the use of the company’s patented DehydraTECH technologyThe company is set to commence dosing its most extensive hypertension study in April 2022, with results expected in Q3 2022Its successful completion could greatly enhance Lexaria’s leadership position in the global drug delivery market Lexaria Bioscience (NASDAQ: LEXX) kicked off the 2022 calendar year by receiving independent review board approval for its upcoming DehydraTECH(TM)-CBD human hypertension study, HYPER-H21-4. Additionally, in what marks another critical milestone, the company also reported ground-breaking findings from its sildenafil animal study. Chris Bunka, the Lexaria’s Chief Executive Officer (“CEO”), at the beginning of the year, noted the company’s commitment to achieving even more milestones with its patented DehydraTECH technology for… Read More>> NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX About CBDWire CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge. Receive Text Alerts from CBDWire: Text “Cannabis” to 21000 For more information please visit https://www.cbdwire.com and or https://CBDWire.News Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer CBDWire (CBDW)Denver, Coloradocbdwire.com303.498.7722 OfficeEditor@CBDWire.com
Lexaria just announced ground-breaking findings from its recently-concluded Sildenafil animal studyThe success of this study sets the stage for various other studies on the use of the company’s patented DehydraTECH technologyThe company is set to commence dosing its most extensive hypertension study in April 2022, with results expected in Q3 2022Its successful completion could greatly enhance Lexaria’s leadership position in the global drug delivery market Lexaria Bioscience (NASDAQ: LEXX) kicked off the 2022 calendar year by receiving independent review board approval for its upcoming DehydraTECH(TM)-CBD human hypertension study, HYPER-H21-4. Additionally, in what marks another critical milestone, the company also reported ground-breaking findings from its sildenafil animal study. Chris Bunka, the Lexaria’s Chief Executive Officer (“CEO”), at the beginning of the year, noted the company’s commitment to achieving even more milestones with its patented DehydraTECH technology for… Read More>> NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX About CBDWire CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge. Receive Text Alerts from CBDWire: Text “Cannabis” to 21000 For more information please visit https://www.cbdwire.com and or https://CBDWire.News Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer CBDWire (CBDW)Denver, Coloradocbdwire.com303.498.7722 OfficeEditor@CBDWire.com